TAK
Takeda Pharmaceutical Company Limited
NYSE Healthcare Japan
17,97 $US
+0.90% today
+15.04% YTD · +23.51% 1Y
20
Insider transactions
SEC Form 4 · AMF · BaFin — rolling 90 days
16
Hedge funds tracked
Latest available SEC 13F filings
65
/ 100
STRONG

Analysis Takeda Pharmaceutical Company Limited (TAK) — Kairos Score 65/100

Composite score aggregating 8 smart money dimensions: insiders (SEC/AMF/BaFin), hedge funds, politicians & gurus, price momentum, valuation, analyst consensus, financial health, earnings momentum. The higher the score, the more favorable the institutional signals consensus.

💡 Detailed breakdown (the 8 sub-scores) available in the Premium dashboard.

About Takeda Pharmaceutical Company Limited

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma-derived therapies, oncology, vaccines, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, EOHILIA, Takhzyro, Advate, Elaprase, Replagal, Vpriv, Adynovate/Adynovi, Livtencity, ADZYNMA, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Flexbumin, Adcetris, Leuplin/Enantone, Ninlaro, Iclusig, FRUZAQLA, Alunbrig, vyvanse/elvanse, Trintellix, and QDENGA brands. It has licensing and collaboration for the development and commercialization of products with Arrowhead Pharmaceuticals, Cour Pharmaceuticals, Engitix, Halozyme, Mirum Pharmaceuticals, Ucsd/Fortis Advisors, Zedira/Dr. Falk Pharma, Ac Immune, Acurastem, Anima Biotech, Biomarin, Denali Therapeutics, Luxna Biotech, Neurocrine Biosciences, Peptidream, Abbvie, Adimab, Ascentage Pharma, Crescendo Biologics, Exelixis, F-Star, Gsk, Heidelberg Pharma, Innovent Biologics, Keros Therapeutics, Kumquat Biosciences, Protagonist Therapeutics, Halozyme, Kamada, Johnson & Johnson/Momenta Pharmaceuticals, Previpharma, Novavax, Bridgene Biosciences, Charles River Laboratories, Iambic Therapeutics, Ipsen, Km Biologics, Massachusetts Institute Of Technology, and Nabla Bio. The company operates in Japan, the United States. Europe, Canada, Latin America, China, Asia, Russia/Commonwealth of Independent States, the Middle East, Oceania, and Africa. The company was founded in 1781 and is headquartered in Chuo, Japan.

Key info

👔
CEO
Ms. Julie Kim
📍
HQ
1-1, Nihonbashi-Honcho 2-chome, Chuo, 103-8668, Japan
👥
Employees
47 029
💰
Market cap
9 006 976 000 000,00 $US
💸
Dividend yield
3.52%

🕴️ Insider activity (90 days)

20 transactions — 0 buys and 20 sales reported by Takeda Pharmaceutical Company Limited executives.

DL
Duprey Lauren Rusckowski
Chief Transformation Officer · 2026-09-14
Sell
PA
Plump Andrew Stewart
President, R&D · 2026-09-02
Sell
PA
Plump Andrew Stewart
President, R&D · 2026-08-19
Sell

🏦 Hedge Funds

16 institutional funds report a position on TAK in their latest SEC quarterly filing.

Capital Research Global Investors
FMR LLC
TIAA CREF INVESTMENT MANAGEMENT LLC
MORGAN STANLEY
ADAGE CAPITAL PARTNERS GP, L.L.C.

📰 Recent news

15 recent articles on TAK.

🧠 What makes Kairos Insider

Beyond raw data, we aggregate and score every smart money signal to give you a unique view.

🧠

Kairos Score 0-100

8-dimension composite score: insiders · hedge funds · politicians · momentum · valuation · health · analysts · earnings.

🎯

Insider Clusters

Detection of clustered purchases or sales by several executives in the same stock.

🏦

13F Hedge Funds

Berkshire, Pershing Square, Tiger Global, Bridgewater and other reporting funds.

📈

ETF Rotations

NANC & GOP (Pelosi & Republicans), GURU (top hedge funds), ARK (Cathie Wood). See who enters and exits each week.

🔥

Google Trends

Spot marked changes in search interest around the stocks being followed.

📧

Email alerts

Create your watchlist and receive a brief of events affecting your tickers.

Companies in the same sector as Takeda Pharmaceutical Company Limited

Official sources · Public data · SEC EDGAR — Form 4 & 13F · AMF — Executive filings · BaFin — Directors' Dealings · Yahoo Finance · Alpha Vantage

🔓 Unlock the full analysis

This public page only shows a preview. The full analysis of TAK on the Kairos Insider dashboard includes:

✅ Full Kairos Score (8-axis radar + synthesis)
✅ History of all 20 insider transactions over 90 days
✅ All 16 detected institutional funds
✅ Thematic ETFs (ARK, BUZZ, NANC, GOP, JEPI…)
✅ Hot Stocks Google Trends
✅ Available history: AUM + rotations
✅ Fundamentals (P/E, PEG, EV/EBITDA, ROE…)
✅ Financial health (Altman Z, Piotroski F)
✅ Sector peers + recent earnings
See full analysis →
Analyze other tickers for free →

Free signup · Pro €19/month or €190/year